



Transparency notification UCB SA/NV

- **Notification referring to situation on 1 April 2021**
- **Threshold crossed: 3%**
- **Latest holding: 2.83%**

Brussels (Belgium), 7 April 2021 – 20:00 (CEST) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification.

The transparency notification dated 7 April 2021 has been submitted in accordance with Article 18 *juncto* Article 6 of the law of 2 May 2007 on the disclosure of large shareholdings, due to UCB covering its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group. As a result thereof, voting rights relating to voting securities held by UCB SA/NV crossed downwards the 3% threshold on 1 April 2021.

On 1 April 2021, UCB SA/NV owned 5 508 556 UCB shares with voting rights (versus 5 855 888 UCB shares in its previous notification dated 29 March 2021), representing 2.83% of the total number of shares issued by the company (194 505 658) (versus 3.01% in the notification dated 29 March 2020).

2. Content of the notification

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights
- **Notification by:** A person that notifies alone
- **Person subject to the notification requirement:**

Name	Address (for legal entities)
UCB SA/NV	Allée de la recherche 60, 1070 Brussels (Anderlecht)

- **Date on which the threshold is crossed:** 1 April 2021
- **Threshold crossed (in %):** 3%
- **Denominator:** 194 505 658

- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
UCB SA/NV	5.855.888	5.508.556		2,83%	
TOTAL		5.508.556	0	2,83%	0,00%

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0,00%	

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	5.508.556
		2,83%

- **Additional information:**

The disclosure obligation arose due to voting rights held by UCB SA crossing downwards the 3% minimum threshold. The variation is due to UCB covering its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB_news](https://twitter.com/UCB_news)